A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis
| Autor: | Genevieve Kelly, Lisa Killion, Emma Tierney, Grainne Callaghan, Paula Evelyn Beatty, Anne-Marie Tobin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry Lymphocyte Progressive multifocal leukoencephalopathy medicine.disease 030226 pharmacology & pharmacy Dermatology 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Fumaric Acid Esters Psoriasis Risk stratification medicine Pharmacology (medical) 030212 general & internal medicine business |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 46:859-861 |
| ISSN: | 1365-2710 0269-4727 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE Fumaric acid esters (FAEs) have been used for fifty years to treat moderate-to-severe psoriasis. However, recent case reports of progressive multifocal leukoencephalopathy, associated with FAE-induced lymphopaenia, have been a cause for concern (J Dtsch Dermatol Ges. 2009;7:603). CASE SERIES We report six cases of persistent lymphopaenia following cessation of treatment with FAEs, with a mean duration of lymphopaenia of 33 months. WHAT IS NEW AND CONCLUSION Given the lack of evidence regarding expected recovery of lymphocyte counts, further research is required to guide physicians in the risk stratification of patients prior to considering treatment with FAEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|